Notes from Previous Releases of USP–NF Online For files that have a USP41-NF36 revision that were superseded by an Accelerated Revision in the November, December, and January monthly posting, the entire document is currently official as of May 1, 2018. Any earlier official date that displays...
Consequently, destroying mutant EZH2 protein may be more effective in targeting EZH2 mutant cancers that are dependent on the non-catalytic activity of EZH2. Here, using extensive selectivity profiling, combined with genetic and animal model studies, we identified USP47 as a novel regulator of ...
19 UBC13 has also been implicated in NF-κB activation19 and p53 cytosolic accumulation,20 which makes it a potentially attractive target for both inflammatory diseases and cancer therapy. Weber and colleagues recently developed a high-throughput assay based on the AlphaScreen technology to identify ...
Therefore, targeting USP28 in combination with cisplatin may be an effective strategy for tumor chemotherapy. AZ1 is a USP28 inhibitor that has been less well studied and is more focused on neurological disorders. In this study, we observed the phenomenon of apoptosis induced by AZ1 alone and ...
Cells were routinely cultured at 37 °C in a humidified atmosphere containing 5% CO2 [47]. Cell lines were authenticated by short tandem repeat profiling and were routinely tested for mycoplasma contamination (Supplementary Data 5). Mouse xenograft model A xenograft model was performed as ...
USP–NFexcipient monographs need to be Up-to-Date to provide maximum benefit to the FDA, manufacturers and users of excipients. Monographs for excipients should be updated periodically to reflect current understanding regarding the role of excipients in new drug...
The use of inhibitors against HAUSP may provide effective outcomes by regulating the Hh pathway in Hh-related cancers.90 NFκB is a master regulator that is central to inflammation, immunity, cell differentiation, survival and proliferation. Thus, its activity is extremely regulated within the cell...
We have demonstrated that enzalutamide and USP14 inhibition synergistically inhibit cell viability in breast cancer cells; this combined growth inhibition effect of the two agents is predominantly due to more effective induction of cell cycle arrest and cell apoptosis. Flow cytometry analysis showed ...
Inactive ingredients: Corn oil-mono-di-triglycerides, DL-α -tocopherol USP, polyoxyl 40 hydrogenated castor oil NF, and propylene glycol USP. The chemical structure of cyclosporine (also known as cyclosporin A) is: CLINICAL PHARMACOLOGY Cyclosporine is a potent immunosuppressive agent that in animals...